Anti-PD-1/PD-L1 targeted therapy is widely used for the treatment of various intractable malignancies and develops therapeutic option in frontier fields oncology treatment. On contrary, these immune checkpoint therapies sometimes develop undesirable adverse reaction as results activation to organs. Herein, we report a case cutaneous reactions during PD-1/PD-L1 both atezolizumab pembrolizumab pa...